Crescita Total Assets from 2010 to 2026

CTX Stock  CAD 0.47  0.02  4.08%   
Crescita Therapeutics Total Assets yearly trend continues to be very stable with very little volatility. Total Assets are likely to grow to about 25.3 M this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals
 
Total Assets  
First Reported
2015-12-31
Previous Quarter
21.9 M
Current Value
21.5 M
Quarterly Volatility
7.1 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 55.6 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.67. Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Crescita Therapeutics Technical models . Check out the analysis of Crescita Therapeutics Correlation against competitors.
Evaluating Crescita Therapeutics's Total Assets across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Crescita Therapeutics's fundamental strength.

Latest Crescita Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Crescita Therapeutics over the last few years. Total assets refers to the total amount of Crescita Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Crescita Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Crescita Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crescita Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 21.78 M10 Years Trend
Slightly volatile
   Total Assets   
       Timeline  

Crescita Total Assets Regression Statistics

Arithmetic Mean18,255,853
Geometric Mean9,833,167
Coefficient Of Variation73.81
Mean Deviation11,784,367
Median24,598,000
Standard Deviation13,475,118
Sample Variance181.6T
Range41.8M
R-Value0.69
Mean Square Error101.4T
R-Squared0.48
Significance0
Slope1,842,251
Total Sum of Squares2905.3T

Crescita Total Assets History

202625.3 M
202525 M
202421.8 M
202324.6 M
202228.5 M
202128.9 M
202026.8 M

About Crescita Therapeutics Financial Statements

Crescita Therapeutics investors utilize fundamental indicators, such as Total Assets, to predict how Crescita Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Assets25 M25.3 M
Intangibles To Total Assets 0.09  0.09 

Other Information on Investing in Crescita Stock

Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.